ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Pfizer invests in gene therapy firm Homology

by Michael McCoy
November 14, 2020 | APPEARED IN VOLUME 98, ISSUE 44

 

Pfizer will pay $60 million for a stake in Homology Medicines, a Bedford, Massachusetts–based firm developing HMI-102, a gene therapy for adults with the metabolic disease phenylketonuria. Homology delivers genes with a suite of adeno-associated virus vectors derived from human hematopoietic stem cellsthat it says are taken up by the body more readily than traditional vectors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment